CommercialCoverageMedium impact
Carotid Sinus Stimulation for Hypertension and Heart Failure (CPB 0820, reviewed 2026-04-07)
Aetna·Cardiology, Internal Medicine, Vascular Surgery +1 more·Medical Policy
Effective date
Apr 7, 2026
We identified it
Aug 14, 2026
Summary
Aetna has classified carotid sinus stimulation devices (Barostim neo, Rheos system) and magnetic stimulation of carotid sinus as experimental, investigational, or unproven for hypertension and heart failure treatment. All related implantation, replacement, revision, removal, and interrogation procedures are NOT COVERED. Device removal for significant complications (pain, infection) is covered, but replacement of investigational devices is not covered.
Action Required
By April 7, 2026: Billing team must implement the following changes: (1) Flag and DENY all claims for CPT codes 0266T, 0267T, 0268T, 0269T, 0270T, 0271T, 0272T, 0273T, 64654, 64655, 64656, 64658, 64659 when billed with ICD-10 diagnoses I10-I16.9 (hypertension) or I50.1-I50.9 (heart failure) for Aetna plans. (2) Update billing software to apply automatic medical necessity rejection with denial reason: 'Procedure classified as experimental, investigational, or unproven by Aetna.' (3) Train providers and front desk staff that carotid sinus stimulation implants and related procedures require member notification of non-coverage prior to service delivery. (4) Create exception pathway: Device REMOVAL claims (CPT 0269T, 0270T, 0271T, 64658, 64659) ARE covered ONLY when documented for significant complications (pain, infection); ensure clinical documentation supports complication-based removal before submission. (5) Do NOT cover device REPLACEMENT procedures under any circumstance; add hard-stop rule in billing system. Failure to implement will result in inappropriate claim payment and compliance issues with Aetna's experimental/investigational service policy.